Literature DB >> 23311227

Phosphate clearance in peritoneal dialysis: automated PD compared with continuous ambulatory PD.

Dixie-Ann Sawin1, Rainer Himmele, Jose A Diaz-Buxo.   

Abstract

Although dialytic removal of phosphate significantly contributes to the management of phosphate levels in end-stage renal disease, many patients on peritoneal dialysis (PD) still do not reach optimal phosphate control. The present review discusses the impact of PD modality--continuous ambulatory (CAPD) or automated (APD)--on phosphate removal. Relevant factors are the diffusive properties of the phosphate anion and the kinetics of phosphate distribution in various body compartments. Confounders that potentially affect comparisons of phosphate clearances in CAPD and APD are differences in residual renal function, membrane transport status, and prescribed dialysis dose. The evidence reviewed here is not strong enough to clearly determine if one modality has a clear advantage with respect to phosphate removal. In the absence of final proof the data suggest that, given the same residual renal function and dialysis dose, CAPD might be slightly more effective than APD at peritoneal phosphate clearance, especially in low transporters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23311227

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  3 in total

1.  Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study.

Authors:  Sunny Eloot; Raymond Vanholder; Clement Dequidt; Wim Van Biesen
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

2.  Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription.

Authors:  Cecile Courivaud; Andrew Davenport
Journal:  Perit Dial Int       Date:  2015-07-29       Impact factor: 1.756

3.  Phosphate clearance in peritoneal dialysis.

Authors:  Malgorzata Debowska; Rafael Gomez; Joyce Pinto; Jacek Waniewski; Bengt Lindholm
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.